Talk:Selective serotonin reuptake inhibitor
This is the talk page for discussing improvements to the Selective serotonin reuptake inhibitor article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1, 2, 3Auto-archiving period: 2 months |
This level-5 vital article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Selective serotonin reuptake inhibitor.
|
Text and/or other creative content from this version of Selective serotonin reuptake inhibitor was copied or moved into Development and discovery of SSRI drugs with this edit. The former page's history now serves to provide attribution for that content in the latter page, and it must not be deleted as long as the latter page exists. |
Merge proposal
editThe following discussion is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.
There have been attempts to recruit editors of specific viewpoints to this article. If you've come here in response to such recruitment, please review the relevant Wikipedia policy on recruitment of editors, as well as the neutral point of view policy. Disputes on Wikipedia are resolved by consensus, not by majority vote. |
- See also Wikipedia:Articles for deletion/Post-SSRI sexual dysfunction ψ Result: Redirect to Selective serotonin reuptake inhibitor#Sexual_dysfunction
- Listed at Proposed mergers
I propose merging Post-SSRI sexual dysfunction into Selective serotonin reuptake inhibitor. This idea has already been floated at WT:MED. The principal reason for the merger is that PSSD is purported to be a medical diagnosis. I don't think publishing a limited number of primary studies is sufficient to establish a diagnosis, no matter how many reviews are published thereafter, especially if the conclusions are summarily rejected by field experts. Rather, a reasonable standard for inclusion would be if the condition is (A) a recognized medical diagnosis OR (B) a widely disseminated fringe/alternative diagnosis, this is clearly neither. The "endorsement" by the EMA does not count towards A, because it is based on a misunderstanding of the limited authority of a medical products agency.
I suggest a limited merger, and it has to be a limited merger with respect to DUE in order to not unbalance the target. Lets keep the historical context, the statement by the EMA and decision concerning the labels, and most importantly be very careful in describing to what extent knowledge about the condition is frought with uncertainty. I'm aware there's already plenty here at the intended target. Essentially this merger is not about adding more, but rather establishing formal consensus for converting PSSD into a redirect for the time being and undertaking a clean up here. Draken Bowser (talk) 11:35, 29 July 2023 (UTC)
- Noting also that there has been WP:ADVOCACY and SPA editing fed by at least two internet fora noted at the WT:MED discussion and on Talk:Post-SSRI sexual dysfunction (some of those posts have been removed from the internet fora, but I have kept archive.org copies). SandyGeorgia (Talk) 12:47, 29 July 2023 (UTC)
Merge. What is left after cleaning out the advocacy editing from the PSSD article says it all in terms of whether Wikipedia should be recognizing it as a separate article:
- The status of PSSD as a legitimate and distinct pathology is contentious; several researchers have proposed that it should be recognized as a separate phenomenon from more common SSRI side effects.[7]
- A 2023 review stated that ongoing sexual dysfunction after SSRI discontinuation was possible, but that cause and effect were undetermined.[3]
- Diagnostic criteria were proposed in 2022,[4] but as of 2023, there is no agreement on standards for diagnosis.[3]
- There is no standard treatment as of 2023, and no evidence that any individual approach is effective.[3]
- As of 2023, prevalence is unknown.[3]
- The biological mechanism underlying the reported symptoms of PSSD is unclear.[6]
- The European Medicines Agency was seriously misconstrued and misrepresented in earlier versions of the PSSD article (which also included SYNTH and non-WP:MEDRS sourcing), and there are reviews that indicate PSSD is not yet defined as a thing separate from the sexual dysfunction already reported for SSRIs, for which there is already a section here at Sexual dysfunction. The article has been heavily edited since late 2022 by at least eight SPAs coming from internet fora, and should go back to the redirect it was before that, until/unless anything about PSSD as a separate condition is established (cause, treatment, diagnosis, prevalence, etc). SandyGeorgia (Talk) 13:02, 29 July 2023 (UTC)
Merge. Adding on what has been said, the content kept in the PSSD article after removal of original research and primary sources is a short text that is necessarily inserted into the current context of sexual dysfunction as a side effect of SSRIs, so that's where it should be located for now. Sto0pinismo0_o 14:01, 29 July 2023 (UTC)
Merge. Per WP:NOPAGE. The previous consensus not to have a standalone article is sound. Bon courage (talk) 16:35, 31 July 2023 (UTC)
Merge. We can't go around letting patients diagnose themselves! --RudolfoMD (talk) 06:39, 3 August 2023 (UTC)